I-Menin Inhibitors: Unyango Olumangalisayo lwe-Acute Myeloid Leukemia

I-Acute myeloid leukemia (AML) yingxaki yegazi eyinkimbinkimbi neyahlukeneyo ebonakaliswa kukwanda kwe-clonal yeeseli ze-myeloid progenitor. Nangona kuqhubekeka unyango, ukunyanga i-AML kusengumngeni, ingakumbi kwizigulana ezineengxaki ezithile zemfuza. Izifundo zakutshanje ziboniswe kwijenali. Igazi zigxininisa ixabiso lezonyango le-Menin inhibitors, zigqamisa amandla azo okuguqula unyango lwe-AML.

Indima ye-Epigenetics kwi-AML

Utshintsho lwe-epigenetic, olufana ne-DNA methylation kunye notshintsho lwe-histone, ziinguqu eziguqukayo ezilawula ukubonakaliswa kwezakhi zofuzo ngaphandle kokutshintsha ulandelelwano lwe-DNA. Olu tshintsho ludlala indima ebalulekileyo ekuphuhlisweni kwe-AML. Ukujolisa kwezi ndlela ze-epigenetic eziguqukayo kunika indlela entsha yonyango.

IiHistones, iiproteni ezibalulekileyo kwiphakheji ye-DNA, ziguqulwa emva kokuguqulwa okufana ne-acetylation kunye ne-methylation, echaphazela ukubhalwa kwezakhi zofuzo. I-Menin, iproteni ye-scaffolding ebhalwe yi-MEN1 gene, ibalulekile kulawulo lwe-epigenetic. Isebenzisana ne-histone methyltransferase KMT2A kunye namanye amaqabane ukulawula ukubonakaliswa kwezakhi zofuzo. Kwi-AML, i-Menin iququzelela iinkqubo zokubhalwa kwezakhi zofuzo ezibangelwa yi-oncogenic, ngakumbi ngokwandiswa kwezakhi zofuzo ze-HOXA kunye ne-MEIS1, eziziinjini eziphambili kwi-KMT2A-rearranged kunye ne-NPM1-mutated AML.

I-Menin Inhibitors: Impumelelo kuNyango lwe-AML

Izithinteli zeMenin ziimolekyuli ezincinci ezikhethwayo kakhulu ezenzelwe ukuphazamisa ukusebenzisana phakathi kweMenin kunye neKMT2A, ngaloo ndlela zivala iindlela zokubhalwa kwe-oncogenic. Ezi zithinteli zibonakalise ukusebenza okumangalisayo kwizifundo zangaphambi kweklinikhi kunye nezeklinikhi, ngakumbi kwi-KMT2A-rearranged kunye ne-NPM1-mutated AML, ezithi ngokudibeneyo zibe yinxalenye ebalulekileyo yamatyala e-AML.

I-Menin inhibitor yokuqala, i-revumenib (SNDX-5613), ivunyiwe ukuba isetyenziswe eklinikhi, kunye nezinye ezininzi, kuquka i-ziftomenib (KO-539) kunye ne-bleximenib, ezivavanywayo. Uvavanyo lwe-AUGMENT-101 lubonise ukuba i-revumenib ifumene izinga lokuphendula elipheleleyo (ORR) lama-53% kwi-relapse okanye i-refractory (R/R) AML, eneziphumo ebezingalindelekanga ezilawulekayo ezifana ne-QTc prolongation kunye ne-differentiation syndrome. Ngokufanayo, iziphumo zokuqala ezivela kuvavanyo lwe-KOMET-001 kunye ne-KOMET-008 ezivavanya i-ziftomenib zibonise amazinga athembisayo okuxolelwa kunye neeprofayili zokhuseleko.

Kukwajongwa unyango oludibeneyo ukuphucula ukusebenza kakuhle kwe-Menin inhibitors. Izifundo ezidibanisa i-revumenib kunye nee-hypomethylating agents ezifana ne-azacitidine kunye ne-venetoclax zibike ukuba amazinga okuphendula asondela kwi-100% kwizigulane ze-AML eziphilileyo nezingafanelekanga, nangona kufuneka ezinye izifundo kunye neeqela ezinkulu.

Imiyalelo yoKhuseleko kunye neXesha elizayo

Izithinteli zeMenin zihlala zibonisa iiprofayili zokhuseleko ezilungileyo, uninzi lweziphumo ebezingalindelekanga ziyalawuleka kwaye ziyaguqulwa. Iziganeko ezimbi eziqhelekileyo ziquka iimpawu zesisu, i-cytopenia, kunye ne-differentiation syndrome. Unyango oluphuhlileyo olunikwe yi-US FDA kwi-revumenib kunye ne-ziftomenib lugxininisa ukubaluleka kwezithinteli zeMenin ekujongeni iimfuno ezingafezekiswanga kunyango lwe-AML.

Idatha yeklinikhi ethembisayo kwi-Menin inhibitors iphawula inyathelo lokutshintsha kunyango lwe-AML, inika ithemba kwizigulana ezineentlobo zemfuza ezinengxaki kwimbali. Njengoko uphando luqhubeka, ezi ndlela zonyango zikulungele ukuchaza kwakhona umgangatho wokhathalelo lwe-AML.

I-BIOOCUS International Medical Center isazimisele ukusebenzisa iindlela ezintsha nezisebenzayo zokuthintela izifo ezifana ne-Menin inhibitors ukuze kunikezelwe unyango olutsha nolusebenzayo kwizigulana kwihlabathi liphela.